Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
Daix (France), New York City (New York, United States), October 6, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral small molecule therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of three abstracts at the upcoming AASLD The Liver Meeting ® 2026, to be held from November 5-9, 2026, in Denver, Colorado.